Tevogen Bio’s (TVGN) Sell (E+) Rating Reiterated at Weiss Ratings

Weiss Ratings restated their sell (e+) rating on shares of Tevogen Bio (NASDAQ:TVGN) in a report published on Wednesday morning,Weiss Ratings reports.

Separately, D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Tevogen Bio in a research report on Thursday, September 4th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $10.00.

Tevogen Bio Price Performance

NASDAQ:TVGN opened at $0.72 on Wednesday. Tevogen Bio has a 1-year low of $0.29 and a 1-year high of $3.09. The company has a 50-day moving average of $0.86 and a 200 day moving average of $1.05. The firm has a market cap of $140.67 million, a PE ratio of -3.76 and a beta of -0.83.

Tevogen Bio (NASDAQ:TVGN) last released its quarterly earnings data on Tuesday, August 19th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02.

Hedge Funds Weigh In On Tevogen Bio

A hedge fund recently bought a new stake in Tevogen Bio stock. Nuveen LLC purchased a new position in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 90,253 shares of the company’s stock, valued at approximately $97,000.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.